ライフサイエンスコーパス: Hodgkin lymphoma

1 -adapted therapy for stage III to IV classic Hodgkin lymphoma.

2 (FL) is the most common form of indolent non-Hodgkin lymphoma.

3 ible diagnostic and predictive biomarkers of Hodgkin lymphoma.

4 omycin; CEC) in patients with advanced-stage Hodgkin lymphoma.

5 ma (DLBCL) is the most common subtype of non-Hodgkin lymphoma.

6 the third most common subtype of B-cell non-Hodgkin lymphoma.

7 nation is not being developed further in non-Hodgkin lymphoma.

8 ssification, applies to both Hodgkin and non-Hodgkin lymphoma.

9 rd rate decreased for Kaposi sarcoma and non-Hodgkin lymphoma.

10 , safe, and active targeted immunotherapy of Hodgkin lymphoma.

11 ractory acute lymphoblastic leukaemia or non-Hodgkin lymphoma.

12 culitis to glomerulonephritis and B-cell non-Hodgkin lymphoma.

13 n patients with relapsed indolent B-cell non-Hodgkin lymphoma.

14 ies of patients with relapsed/refractory non-Hodgkin lymphoma.

15 lymphoma (ALCL) is an aggressive CD30(+) non-Hodgkin lymphoma.

16 d leukaemia, and 0.940 (0.897-0.984) for non-Hodgkin lymphoma.

17 rvous system lymphoma, and 7 (13%) other non-Hodgkin lymphoma.

18 ive as monotherapy for relapsed indolent non-Hodgkin lymphoma.

19 to testicular cancer; and 829396 due to non-Hodgkin lymphoma.

20 nts with relapsed CD37-positive indolent non-Hodgkin lymphoma.

21 central to the evaluation of Hodgkin and non-Hodgkin lymphoma.

22 (MPNs), non-Hodgkin lymphomas, and classical Hodgkin lymphoma.

23 or patients with relapsed CD37+ indolent non-Hodgkin lymphoma.

24 ) EZH2 mutations have been identified in non-Hodgkin lymphomas.

25 onjugate, in relapsed/refractory CD30(+) non-Hodgkin lymphomas.

26 uncommon yet devastating complication of non-Hodgkin lymphomas.

27 1.0% and 1.5%; liver cancer, 1.1% and 0.4%; Hodgkin lymphoma, 0.9% and 0.09%; melanoma, 0.5% and 0.6

28 aposi's sarcoma [498.11, 477.82-519.03], non-Hodgkin lymphoma [11.51, 11.14-11.89], and cervix [3.24,

29 2.4%), follicular lymphomas (15.3%), classic Hodgkin lymphomas (13%), peripheral T-cell lymphomas (6.

30 ear survival was 42% lower for secondary non-Hodgkin lymphoma, 19% for secondary breast carcinoma, 15

31 r AIDS-defining cancers (ADCs, including non-Hodgkin lymphoma, 2.0% of deaths) and 7.1% for non-AIDS-

32 Of these, 12 (21%) had Hodgkin lymphoma, 22 (39%) diffuse large B-cell lymphoma

33 follows: Kaposi sarcoma, 4.4% and 0.01%; non-Hodgkin lymphoma, 4.5% and 0.7%; lung cancer, 3.4% and 2

34 breast cancer (92 patients, 426 scans), non-Hodgkin lymphoma (77 patients, 208 scans), Hodgkin disea

35 breast cancer (92 patients, 426 scans), non-Hodgkin lymphoma (77 patients, 208 scans), Hodgkin disea

36 ular lymphoma (FL) is an indolent B-cell non-Hodgkin lymphoma able to transform into germinal center-

37 Survivors of Hodgkin lymphoma, acute myeloid leukaemia, genitourinary

38 patients for thyroid, Hodgkin lymphoma, non-Hodgkin lymphoma, acute myeloid leukemia, soft-tissue sa

39 Among survivors of Hodgkin lymphoma aged over 60 years, almost 30% of the t

40 An EL4 mouse model of non-Hodgkin lymphoma and a B16 mouse model of subcutaneous m

41 -Hodgkin lymphomas or a combination of a non-Hodgkin lymphoma and a Hodgkin's lymphoma.

42 Twenty-six patients with advanced non-Hodgkin lymphoma and acute lymphoblastic leukemia safely

43 promising results in phase 2 trials in CD30+ Hodgkin lymphoma and anaplastic large cell lymphoma.

44 ablished therapeutic target in patients with Hodgkin lymphoma and anaplastic large-cell lymphoma.

45 Up to 50% of patients with Hodgkin lymphoma and diffuse large B-cell lymphoma will

46 ggressive lymphoma (nine of 26 patients with Hodgkin lymphoma and eight of 20 patients with diffuse l

47 ta regarding transplantation in indolent non-Hodgkin lymphoma and highlights the issues relevant to c

48 is approach as a screening technique for non-Hodgkin lymphoma and melanoma skin cancer.

49 raising concerns about associations with non-Hodgkin lymphoma and multiple myeloma.

50 g data set including 249 cases of T-cell non-Hodgkin lymphoma and normal T cells.

51 In contrast to Hodgkin lymphoma and systemic anaplastic large-cell lymp

52 transplantation for Hodgkin lymphoma or non-Hodgkin lymphoma and targeted sequencing on cryopreserve

53 nderstanding the biology and genetics of non-Hodgkin lymphoma and the availability of new diagnostic

54 ed for the treatment of relapsed, refractory Hodgkin lymphomas and systemic anaplastic large T-cell l

55 diagnoses were acute lymphoblastic leukemia, Hodgkin lymphoma, and astrocytoma.

56 , as well as leukemia, multiple myeloma, non-Hodgkin lymphoma, and breast cancer in postmenopausal wo

57 12 for Kaposi's sarcoma, two subtypes of non-Hodgkin lymphoma, and cancer of the anus, liver, and lun

58 durable responses in relapsed/refractory non-Hodgkin lymphoma, and combination with rituximab and oth

59 uximab is the standard of care in B-cell non-Hodgkin lymphoma, and is administered over 1.5-6 h.

60 nces by age 75 years for Kaposi sarcoma, non-Hodgkin lymphoma, and lung cancer support early and sust

61 creasing hazard rate trends for lung cancer, Hodgkin lymphoma, and melanoma, cumulative incidence tre

62 optosis in acute myeloid leukemia (AML), non-Hodgkin lymphoma, and multiple myeloma cells.

63 leukemia, chronic lymphocytic leukemia, non-Hodgkin lymphoma, and multiple myeloma) and 9 treatment

64 itt lymphoma, diffuse large B-cell lymphoma, Hodgkin lymphoma, and primary mediastinal B-cell lymphom

65 ces potent cell death in T-cell lymphoma and Hodgkin lymphoma, and we identified that combinatorial t

66 S), myeloproliferative neoplasms (MPNs), non-Hodgkin lymphomas, and classical Hodgkin lymphoma.

67 al cell cancers and most breast cancers, non-Hodgkin lymphomas, and medullary thyroid cancers represe

68 the treatment of advanced stages of this non-Hodgkin lymphoma are clearly warranted.

69 l cancer, leukaemia, thyroid cancer, and non-Hodgkin lymphomas are the most common cancers affecting

70 city, warranting further study in B-cell non-Hodgkin lymphoma as a platform for addition of novel age

71 Bone marrow showed clear non-Hodgkin lymphoma as the underlying disorder in 54% of pa

72 EBV-associated cancers, such as Burkitt and Hodgkin lymphoma, as well as nasopharyngeal carcinoma.

73 myeloid leukaemias, Hodgkin's lymphomas, non-Hodgkin lymphomas, astrocytomas, Ewing's sarcomas, and r

74 d/refractory B-cell malignancies such as non-Hodgkin lymphoma (B-NHL) or acute lymphoblastic leukemia

75 hosphorylation may be involved in B-cell non-Hodgkin lymphoma (B-NHL) pathogenesis is largely unknown

76 phoma (BL) is a highly aggressive B-cell non-Hodgkin lymphoma (B-NHL), which originates from germinal

77 the pathogenesis of many types of B-cell non-Hodgkin lymphoma (B-NHL).

78 ransformation and is a driver for B-cell non-Hodgkin lymphoma (B-NHL).

79 We have shown that human B-cell non-Hodgkin lymphomas (B-NHLs) express heat shock protein (H

80 from 401 patients who underwent ASCT for non-Hodgkin lymphoma between 2003 and 2010.

81 rs derived from sophisticated exploration of Hodgkin lymphoma biology is bringing promise of further

82 ostate, colorectal, non-small-cell lung, non-Hodgkin lymphoma, breast, uterine, or cervical) from 201

83 D27 is expressed on a majority of B-cell non-Hodgkin lymphoma, but its role in the immune control of

84 mprove responses in patients with B-cell non-Hodgkin lymphoma, but our findings need confirmation in

85 the constitutive CCL17 secretion of a human Hodgkin lymphoma cell line and prevent upregulation of c

86 inhibitor, ixazomib, in T-cell lymphoma and Hodgkin lymphoma cells and in vivo SCID mouse models.

87 lymphoma (MCL) is a distinct subtype of non-Hodgkin lymphoma characterized by overexpression of cycl

88 odgkin and Reed-Sternberg cells of classical Hodgkin lymphoma (CHL) (uniform CD50 and variable CD58 f

89 f late relapse (LR) in patients with classic Hodgkin lymphoma (cHL) are poorly understood.

90 aim was to capture the biology of classical Hodgkin lymphoma (cHL) at the time of relapse and discov

91 Reed-Sternberg (RS) cells of classical Hodgkin lymphoma (cHL) express multiple immunoregulatory

92 Classic Hodgkin lymphoma (cHL) has few known modifiable risk fac

93 Classical Hodgkin lymphoma (cHL) is an unusual B-cell-derived mali

94 Classical Hodgkin lymphoma (cHL) is characterized by sparsely dist

95 grammed death 1 (PD-1) blockade in classical Hodgkin lymphoma (cHL) patients, anti-PD-1 monoclonal an

96 hin the inflammatory background in classical Hodgkin lymphoma (cHL) provide signals essential for the

97 Studies in classical Hodgkin lymphoma (cHL) typically measure the time to eve

98 andard front-line chemotherapy for classical Hodgkin lymphoma (cHL), a subset of these patients, part

99 lls to evade antitumor immunity in classical Hodgkin lymphoma (cHL).

100 ety of B-cell lymphomas, including classical Hodgkin lymphoma (cHL).

101 Classical Hodgkin lymphomas (cHLs) include small numbers of malign

102 ients with relapsed or refractory kappa+ non-Hodgkin lymphoma/chronic lymphocytic leukemia (NHL/CLL)

103 Non-Hodgkin lymphoma comprises a variety of neoplasms, many

104 val of rituximab for treatment of B cell non-Hodgkin lymphoma, development of monoclonal antibodies (

105 s worldwide and approximately 30% of the non-Hodgkin lymphomas diagnosed in the United States.

106 rian carcinoma, a follicular lymphoma, and a Hodgkin lymphoma, each confirmed by subsequent pathologi

107 consists of mainly 4 subtypes of B-cell non-Hodgkin lymphoma: EMZL, FL, MCL, and DLBCL.

108 vedotin in patients with relapsed/refractory Hodgkin lymphoma following autologous stem cell transpla

109 Patients with advanced-stage Hodgkin lymphoma for whom treatment was at high risk of

110 mas (PTCLs) are a heterogeneous group of non-Hodgkin lymphomas frequently associated with poor progno

111 ladder, pancreatic, or gastric cancer or non-Hodgkin lymphoma from 2002 to 2011.

112 The resulting non-Hodgkin lymphoma gene sensor showed a detection limit of

113 hly selective, label-free sensor for the non-Hodgkin lymphoma gene, with an aM detection limit, utili

114 Treatment of non-Hodgkin lymphoma has changed profoundly, benefiting pati

115 The treatment of non-Hodgkin lymphomas has benefited enormously from the intr

116 Several susceptibility loci for classical Hodgkin lymphoma have been reported.

117 ults, we confirm that patients with advanced Hodgkin lymphoma have similar OS results when treated wi

118 to intensify chemotherapy in aggressive non-Hodgkin lymphomas have, however, proved ineffective in p

119 Adolescents and young adults with secondary Hodgkin lymphoma (hazard ratio [95% CI], 3.5 [1.7-7.1]);

120 HIV-associated classical Hodgkin lymphoma (HIV-cHL) is an important complication

121 ion in a large prospective clinical trial in Hodgkin lymphoma (HL) (Response-Adapted Therapy in Advan

122 n in patients with relapsed/refractory (R/R) Hodgkin lymphoma (HL) after failed hematopoietic autolog

123 have shown associations between the risk of Hodgkin lymphoma (HL) and a history of autoimmune and at

124 Targeting CD30 with monoclonal antibodies in Hodgkin lymphoma (HL) and anaplastic large cell lymphoma

125 ab vedotin in the treatment of patients with Hodgkin lymphoma (HL) and anaplastic large-cell lymphoma

126 Hodgkin lymphoma (HL) and Burkitt lymphoma are both germ

127 d fatigue occurs frequently in patients with Hodgkin lymphoma (HL) and has a major impact on their qu

128 gical syndromes (PNSs) rarely associate with Hodgkin lymphoma (HL) and non-HLs (NHLs).

129 ng, and response assessment of patients with Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL).

130 Long-term survivors of Hodgkin lymphoma (HL) are at an increased risk for a ran

131 assessment and end of treatment in pediatric Hodgkin lymphoma (HL) are limited.

132 particular, the results of PD-1 blockade in Hodgkin lymphoma (HL) are remarkable, and raise hope tha

133 ed to provide the familial risk of classical Hodgkin lymphoma (HL) by relationship, histology, age at

134 ariations in incidence and mortality after a Hodgkin lymphoma (HL) diagnosis have been previously des

135 Purpose Classical Hodgkin lymphoma (HL) frequently exhibits genetic altera

136 mbined modality treatment for stage I and II Hodgkin lymphoma (HL) have an excellent outcome.

137 tients aged >/=60 years with treatment-naive Hodgkin lymphoma (HL) have few treatment options and inf

138 et al introduce a new principle of targeted Hodgkin lymphoma (HL) immunotherapy in their report from

139 Hodgkin lymphoma (HL) is a highly curable form of childh

140 Hodgkin lymphoma (HL) is a malignancy of germinal center

141 actors for patients with relapsed/refractory Hodgkin lymphoma (HL) is essential for optimizing therap

142 Hodgkin lymphoma (HL) is one of the most curable pediatr

143 e in the treatment of patients with advanced Hodgkin lymphoma (HL) is unclear, and the impact of dose

144 orried that pregnancy after the diagnosis of Hodgkin lymphoma (HL) may increase the risk of relapse d

145 (11)C-MET) in children and young adults with Hodgkin lymphoma (HL) or non-Hodgkin lymphoma (NHL) and

146 using bleomycin has been questioned in older Hodgkin lymphoma (HL) patients, especially in early-stag

147 (CMT) and chemotherapy alone for early-stage Hodgkin lymphoma (HL) remains controversial.

148 Hodgkin lymphoma (HL) survivors treated with radiotherap

149 Hodgkin lymphoma (HL) survivors treated with thoracic ra

150 Outcomes in older patients with Hodgkin lymphoma (HL) tend to be poor following conventi

151 Purpose Although advances in Hodgkin lymphoma (HL) treatment have led to improved dis

152 e increasingly recognized as late effects of Hodgkin lymphoma (HL) treatment.

153 ociated with an increased risk of developing Hodgkin lymphoma (HL) we analysed 589 HL cases and 5,199

154 esponse evaluation criteria in patients with Hodgkin lymphoma (HL) were designed for the assessment o

155 with newly diagnosed, early stage classical Hodgkin lymphoma (HL) with unfavorable-risk features wer

156 acute lymphoblastic leukemias), 12 developed Hodgkin lymphoma (HL), 38 developed non-Hodgkin lymphoma

157 nsidered the standard of care in early-stage Hodgkin lymphoma (HL), and treatment intensity has been

158 The presence of bulky disease in Hodgkin lymphoma (HL), traditionally defined with a 1-di

159 SCT) in patients with relapsed or refractory Hodgkin lymphoma (HL).

160 ted tomography (PET-CT) should replace CT in Hodgkin lymphoma (HL).

161 with relapsed or refractory (R/R) classical Hodgkin lymphoma (HL).

162 atients with stage I or II bulky mediastinal Hodgkin lymphoma (HL).

163 ted for patients with relapsed or refractory Hodgkin lymphoma (HL).

164 consolidating radiotherapy in advanced-stage Hodgkin lymphoma (HL).

165 important reason for upstaging by PET/CT in Hodgkin lymphoma (HL).

166 onic lymphocytic leukaemia (CLL, N = 1,842), Hodgkin lymphoma (HL, N = 1,465) and multiple myeloma (M

167 ively defined as non-Hodgkin lymphoma [NHL], Hodgkin lymphoma [HL], and chronic lymphocytic leukemia

168 lymphocytic leukemia, multiple myeloma, non-Hodgkin lymphoma, Hodgkin lymphoma, myeloproliferative n

169 loma (HR, 1.28 [95% CI, 1.01-1.62]), and non-Hodgkin lymphoma (HR, 1.16 [95% CI, >1.00-1.35]) cancers

170 and improved survival in T-cell lymphoma and Hodgkin lymphoma human lymphoma xenograft models.

171 ymphoma (FL) is the most common indolent non-Hodgkin lymphoma in the Western hemisphere.

172 lymphoma (FL) is the second most common non-Hodgkin lymphoma in the Western world.

173 line therapy in patients with advanced-stage Hodgkin lymphoma, in terms of providing a rationale to s

174 phase (n = 179), patients with indolent non-Hodgkin lymphoma (iNHL), chronic lymphocytic leukemia (C

175 dy in 64 patients with relapsed indolent non-Hodgkin lymphoma (iNHL).

176 the lung/bronchus (IRR, 1.58; P < .01), non-Hodgkin lymphoma (IRR, 1.41; P < .01), and breast cancer

177 of follicular lymphoma to an aggressive non-Hodgkin lymphoma is a critical biologic event with profo

178 Treatment of Hodgkin lymphoma is associated with 2 major types of ris

179 Risk assessment in Hodgkin lymphoma is continuously evolving, promising eve

180 Worldwide, B cell non-Hodgkin lymphoma is the most common hematological malign

181 oma, the most common indolent subtype of non-Hodgkin lymphoma, is associated with a relatively long o

182 nts with limited-stage aggressive B-cell non-Hodgkin lymphoma (LD-NHL).

183 lymphoma (PEL) is an aggressive type of non-Hodgkin lymphoma localized predominantly in body cavitie

184 h low-risk, pediatric lymphocyte-predominant Hodgkin lymphoma (LPHL) with a strategy of resection alo

185 performed a comprehensive analysis of LR of Hodgkin lymphoma (LR-HL).

186 attributable deaths were associated with non-Hodgkin lymphoma, lung cancer, and liver cancer.

187 inary cancers other than bladder cancer, non-Hodgkin lymphoma, lung cancer, leukaemia other than acut

188 In 15 non-Hodgkin lymphomas, many more sst2 sites were labeled wit

189 ant for cell survival in T-cell lymphoma and Hodgkin lymphoma models.

190 thyroid; mesothelioma; Hodgkin lymphoma; non-Hodgkin lymphoma; multiple myeloma; leukemia; and all ot

191 mia, multiple myeloma, non-Hodgkin lymphoma, Hodgkin lymphoma, myeloproliferative neoplasms, and myel

192 ic lymphocytic leukemia (CLL; n = 41) or non-Hodgkin lymphoma (n = 145).

193 ronic lymphocytic leukemia (n = 24), and non-Hodgkin lymphoma (n = 62).

194 se large B-cell lymphoma (n = 10), classical Hodgkin lymphoma (n = 9), and reactive lymphadenitis (n

195 eloid leukemia (n=65), 39% in aggressive non-Hodgkin lymphoma (n=83), and 37% in indolent or mantle-c

196 oma; n = 537), P9425 (intermediate/high-risk Hodgkin lymphoma; n = 216), and P9426 (low-risk Hodgkin

197 gkin lymphoma; n = 216), and P9426 (low-risk Hodgkin lymphoma; n = 255) were conducted between 1996 a

198 lanoma (RR = 8.75; 95% CI: 1.89, 40.53), non-Hodgkin lymphoma (NHL) (RR = 2.69; 95% CI: 1.33, 5.45),

199 ung adults with Hodgkin lymphoma (HL) or non-Hodgkin lymphoma (NHL) and compared the biodistribution

200 adjusted incidence rate ratios (aIRR) of non-Hodgkin lymphoma (NHL) and other cancers with increased

201 Central nervous system (CNS) relapse in non-Hodgkin lymphoma (NHL) carries a very poor prognosis.

202 yndrome (pSS) confers increased risk for non-Hodgkin lymphoma (NHL) development.

203 mmunotherapy (PRIT) that targets CD20 in non-Hodgkin lymphoma (NHL) exhibits remarkable efficacy in m

204 association between benzene exposure and non-Hodgkin lymphoma (NHL) has been the subject of debate as

205 tients with relapsed or refractory (R/R) non-Hodgkin lymphoma (NHL) have a poor prognosis and limited

206 studies have reported that survivors of non-Hodgkin lymphoma (NHL) have an increased risk of develop

207 ients with relapsed or refractory B-cell non-Hodgkin lymphoma (NHL) have an unfavourable prognosis wi

208 Treatment and prognosis of pediatric non-Hodgkin lymphoma (NHL) have improved dramatically in the

209 987-2014), we studied PCNSL and systemic non-Hodgkin lymphoma (NHL) in 288 029 solid organ transplant

210 Little is known about the risk of non-Hodgkin lymphoma (NHL) in nonsmokers who are exposed to

211 Background: Non-Hodgkin lymphoma (NHL) is the most common AIDS-defining

212 Non-Hodgkin lymphoma (NHL) is the most common AIDS-defining

213 Non-Hodgkin lymphoma (NHL) is the most commonly diagnosed he

214 Dietary fat intake may contribute to non-Hodgkin lymphoma (NHL) pathogenesis by influencing carci

215 the burden of Kaposi's sarcoma (KS) and non-Hodgkin lymphoma (NHL) relative to antiretroviral therap

216 n immune system-altering experiences and non-Hodgkin lymphoma (NHL) risk using a case-control study o

217 Several non-Hodgkin lymphoma (NHL) subtypes, including diffuse large

218 (BCL-2) overexpression is common in many non-Hodgkin lymphoma (NHL) subtypes.

219 d the improved survival of patients with non-Hodgkin lymphoma (NHL), relapses or primary refractory d

220 In murine xenograft models of MM and non-Hodgkin lymphoma (NHL), the CD38-bispecific construct de

221 In Non-Hodgkin Lymphoma (NHL), the prevalence of OBI reactivati

222 d chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL), they require prolonged administr

223 oped Hodgkin lymphoma (HL), 38 developed non-Hodgkin lymphoma (NHL), three developed T-cell prolympho

224 is associated with an increased risk of non-Hodgkin lymphoma (NHL).

225 a potential novel risk factor for B-cell non-Hodgkin lymphoma (NHL).

226 inatumomab in relapsed/refractory B-cell non-Hodgkin lymphoma (NHL).

227 c variations are associated with risk of non-Hodgkin lymphoma (NHL).

228 suspected environmental risk factors for non-Hodgkin lymphoma (NHL).

229 well established for adult patients with non-Hodgkin lymphoma (NHL).

230 ty of this agent in patients with B-cell non-Hodgkin lymphoma (NHL).

231 patients with relapsed/refractory B-cell non-Hodgkin lymphoma (NHL).

232 patients with Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL).

233 resent attractive targets for therapy in non-Hodgkin lymphoma (NHL).

234 th heart failure (HF) among survivors of non-Hodgkin lymphoma (NHL).

235 y for relapsed intermediate-grade B-cell non-Hodgkin lymphoma (NHL); however, relapse rates are high.

236 ion to lymphoma (collectively defined as non-Hodgkin lymphoma [NHL], Hodgkin lymphoma [HL], and chron

237 ctivity of 22% to 68% in relapsed B-cell non-Hodgkin lymphoma(NHL).

238 Non-Hodgkin lymphomas (NHLs) are the most common cancer to a

239 LDR) of 46 patients with indolent B-cell non-Hodgkin lymphomas (NHLs) or chronic lymphocytic leukemia

240 Nodular lymphocyte Hodgkin lymphoma (NLPHL) is a rare disease for which the

241 t of stage IA nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is not well defined.

242 propensity of nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) to transform into diffuse large

243 dvanced-stage nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL).

244 s involved by nodular lymphocyte predominant Hodgkin lymphoma (NLPHL).

245 se in younger vs older patients for thyroid, Hodgkin lymphoma, non-Hodgkin lymphoma, acute myeloid le

246 n and nervous system; thyroid; mesothelioma; Hodgkin lymphoma; non-Hodgkin lymphoma; multiple myeloma

247 closely resemble those of nodular sclerosing Hodgkin lymphoma (NSHL).

248 Cutaneous T cell lymphoma (CTCL) is a non-Hodgkin lymphoma of skin-homing T lymphocytes.

249 s T-cell lymphoma (CTCL) is an incurable non-Hodgkin lymphoma of the skin-homing T cell.

250 ped TMN after autologous transplantation for Hodgkin lymphoma or non-Hodgkin lymphoma and targeted se

251 ite lymphomas can be combinations of two non-Hodgkin lymphomas or a combination of a non-Hodgkin lymp

252 d cancer-specific mortality for anal cancer, Hodgkin lymphoma, or diffuse large B-cell lymphoma.

253 herapy and a diagnosis of breast cancer, non-Hodgkin lymphoma, or gynecologic cancers.

254 acute lymphoid leukaemia (p<0.0001) and non-Hodgkin lymphoma (p<0.0001 in AYAs and p=0.023 in childr

255 east, lung/bronchus, endometrial, colon, non-Hodgkin lymphoma, pancreas, kidney/renal pelvis, rectum,

256 130 tumors in 39 relapsed or refractory non-Hodgkin lymphoma patients by coupling SPECT/CT imaging w

257 st of bacteria that promote human B-cell non-Hodgkin lymphoma, possibly by the infection of pDCs and

258 lymphoma (MCL) is an uncommon subtype of non-Hodgkin lymphoma previously considered to have a poor pr

259 relapsed or refractory peripheral T-cell non-Hodgkin lymphoma (PTCL).

260 trial: Response-Adapted Therapy in Advanced Hodgkin Lymphoma (RATHL).

261 a (HL) (Response-Adapted Therapy in Advanced Hodgkin Lymphoma [RATHL]).

262 th heavily pretreated relapsed or refractory Hodgkin lymphoma received AFM13 at doses of 0.01 to 7 mg

263 A middle-aged man with non-Hodgkin lymphoma received chemotherapy and a stem cell t

264 cally documented, CD20-positive indolent non-Hodgkin lymphoma refractory to rituximab were enrolled a

265 Non-Hodgkin lymphoma represents a wide spectrum of illnesses

266 international, multicohort retrospective non-Hodgkin lymphoma research study, retrospectively evaluat

267 ts overexpressed in multiple myeloma and non-Hodgkin lymphoma, respectively.

268 in cancer (RR, 1.93; 95% CI, 1.86-2.00), and Hodgkin lymphoma (RR, 1.87; 95% CI, 1.80-1.94).

269 01, Val86 in HLA-DRB1) and mixed cellularity Hodgkin lymphoma (rs1633096, rs13196329, Val86 in HLA-DR

270 LA region are observed for nodular sclerosis Hodgkin lymphoma (rs9269081, HLA-DPB1*03:01, Val86 in HL

271 ed in studies from the German High-Grade Non-Hodgkin Lymphoma Study Group and the MabThera Internatio

272 justed IPI 2,3) of the German High-Grade Non-Hodgkin Lymphoma Study Group were analyzed with the Lymp

273 domisation scheme stratified by indolent non-Hodgkin lymphoma subtype, rituximab-refractory type, num

274 lds may require inclusion of homogeneous non-Hodgkin lymphoma subtypes to account for differences in

275 dynamics, we characterized two exemplary non-Hodgkin lymphoma subtypes with comparable CD20 expressio

276 so demonstrated efficacy in other B-cell non-Hodgkin lymphoma subtypes, in particular mantle cell lym

277 tries and allowed reporting on the major non-Hodgkin lymphoma subtypes.

278 elodysplastic syndromes, acute leukemia, non-Hodgkin lymphomas such as chronic lymphocytic leukemia,

279 5% CI, 25 to 34), with a 35% incidence among Hodgkin lymphoma survivors (95% CI, 29 to 40).

280 Blood, van Eggermond et al demonstrate that Hodgkin lymphoma survivors who develop a second malignan

281 static breast cancer, relapsed or refractory Hodgkin lymphoma, systemic anaplastic large cell lymphom

282 ma (NKTCL) is a rare, aggressive form of non-Hodgkin lymphoma that is generally incurable at more adv

283 oma (PCNSL) is a rare form of extranodal non-Hodgkin lymphoma that is typically confined to the brain

284 d leukemia, myelodysplastic syndrome, or non-Hodgkin lymphoma, the three most common indications for

285 erall survival of patients with indolent non-Hodgkin lymphomas, these lymphomas remain largely incura

286 PET-guided therapy has improved outcomes in Hodgkin lymphoma, using less chemotherapy and more selec

287 tuximab in patients with indolent B-cell non-Hodgkin lymphoma was tolerable but did not lead to incre

288 ents with relapsed CD37+ indolent B-cell non-Hodgkin lymphoma were included for RM dosimetry.

289 ents with relapsed/refractory aggressive non-Hodgkin lymphoma were randomized to GDP or DHAP; 87 pati

290 unts for about 10% of all lymphomas) and non-Hodgkin lymphoma, which is the topic of this Seminar.

291 Patients with indolent non-Hodgkin lymphoma who fail to achieve adequate disease co

292 pose To compare the outcome of patients with Hodgkin lymphoma who received post-transplantation cyclo

293 spectively evaluated 709 adult patients with Hodgkin lymphoma who were registered in the European Soc

294 s (age >/=18 years) with indolent B-cell non-Hodgkin lymphoma with stable disease or better lasting a

295 mas (PTCLs) represent a diverse group of non-Hodgkin lymphomas with a poor prognosis and no accepted

296 ) is a heterogeneous group of aggressive non-Hodgkin lymphomas with poor outcomes on current therapy.

297 uximab-refractory patients with indolent non-Hodgkin lymphoma, with manageable toxicity, and is a new

298 oma (FL) represents more than 20% of all non-Hodgkin lymphomas worldwide and approximately 30% of the

299 ma (DLBCL) is the most common subtype of non-Hodgkin lymphoma, yet 40% to 50% of patients will eventu

300 (FL) is the most common form of indolent non-Hodgkin lymphoma, yet it remains only partially characte